2025-11-16 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the data you provided. The report will be in English, starting with key figures and moving to a more detailed analysis.

**Report on TransMedics Group Inc. (TMDX)**

**1. Performance Overview vs. S&P 500 (VOO)**

*   **Ticker:** TMDX
*   **Company Description:** TransMedics Group Inc. is a medical technology company pioneering a novel approach to organ transplant therapy.
*   **TMDX Cumulative Return:** 185.62%
*   **VOO Cumulative Return:** 73.88%
*   **Spread (Outperformance):**
    *   Current: 111.74% (185.62% - 73.88%)
    *   Max: 247.2
    *   Min: -74.5
    *   Current Spread: 111.74
    *   Relative Spread: 67.0

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the tracked period. The relative spread of 67.0 indicates that the current outperformance is positioned above the historical median, suggesting strong relative performance compared to its own history.

**2. Alpha, Beta Analysis & Key Metrics**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2019-2021  | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%   | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%   | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0%  | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 106.0%  | 85.5% | 43.0%  | 0.3  | 4.0    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows substantial growth in recent periods (2020-2025).
*   **MDD:**  High Maximum Drawdown (MDD) values across all periods indicate significant volatility and risk.
*   **Alpha:**  Positive Alpha values suggest that TMDX has consistently outperformed its benchmark on a risk-adjusted basis, particularly strong in 2020-2024. A recent drop of alpha in 2023-2025 indicates alpha generation could be under pressure.
*   **Beta:** Low Beta values suggest that TMDX's price is not highly correlated with the overall market.

**3. Recent Stock Price Movement**

*   **Current Price:** 115.01
*   **Previous Close:** 115.55
*   **Change:** -0.47
*   **5-Day Moving Average:** 118.854
*   **20-Day Moving Average:** 124.631
*   **60-Day Moving Average:** 117.7792

**Analysis:** The current price is slightly down compared to the previous close. The 5-day moving average is below the 20-day moving average, which suggests a short-term downward trend. The price is below the 60-day moving average, further supporting a downward trend.

**4. Market Risk Indicators and Signals**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 29.03 (Oversold)
*   **PPO:** -1.39 (Negative)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (8 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Delta_Previous_Relative_Divergence:** -5.5 (Negative - Short-term Decline)
*   **Expected Return:** 42.8% (Long-term, vs. S&P 500)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates that the stock is currently oversold, which can sometimes signal a potential buying opportunity.
*   The negative PPO suggests that the short-term moving average is below the long-term moving average, indicating a downward trend.
*   Hybrid signal recommends buying with all cash.
*   The negative change in relative divergence supports the downward trend.
*   Despite the short-term indicators, the expected return is high (42.8%), suggesting potential long-term outperformance.
*   The small change in price from the previous close (-0.47) does not indicate a significant volatility event.

**5. Recent News & Significant Events**

*   **Value Picks & Intrinsic Value:** Several articles highlight TMDX as potentially undervalued, estimating that the shares could be trading significantly below their intrinsic value.
*   **Inducement Grants:**  A recent report discusses inducement grants, which are often used to attract and retain talent.

**6. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.67 (~Buy)
*   **Opinions:** 11
*   **Target Price:**
    *   Average: 141.91
    *   High: 170.00
    *   Low: 114.00
*   **Recent Rating Changes:** No changes indicated in the provided data.

**Analysis:**  Analysts generally have a positive outlook on TMDX, with a consensus rating of "Buy" and an average target price significantly above the current price. The target price range indicates a mix of expectations, but even the low target is near the current price.

**Overall Summary**

TMDX has shown strong historical outperformance compared to the S&P 500, with a high cumulative return. However, it also exhibits high volatility (MDD). Recent price action suggests a short-term downward trend, with the RSI indicating oversold conditions. Market Risk Indicator suggests medium risk. Analyst opinions are generally positive, with a "Buy" consensus and a significant upside to the average target price. Recent news highlights the potential undervaluation of the stock.

**Recommendation:**

Based on this analysis, TMDX appears to be a potentially attractive investment, particularly for investors with a long-term horizon. While short-term indicators suggest caution, the strong historical performance, positive analyst outlook, and potential undervaluation highlighted in recent news are encouraging. Given the high MDD, it's crucial to consider risk tolerance before investing.
